NSRX
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Nasus Pharma Ltd. (NSRX) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | D+ (1.8) | D- (0.8) | C (2.5) | C+ (2.6) | C- (2.1) |
| 2026-11-06 | C+ (2.5) | D+ (1.8) | D- (0.8) | C+ (2.7) | C+ (2.7) | C- (2.1) |
| 2026-10-30 | C+ (2.5) | D+ (1.8) | D- (1.0) | B- (3.1) | C+ (2.7) | C (2.2) |
| 2026-10-23 | C+ (2.5) | C- (1.9) | D- (0.9) | C+ (2.7) | C+ (2.6) | C- (2.1) |
| 2026-10-16 | C+ (2.5) | D+ (1.8) | D- (0.9) | B (3.2) | C+ (2.6) | C (2.2) |